Scarica l'app Stockscreener
30.14
2.93%
-0.91
Dopo l'orario di chiusura:
30.14
Precedente Chiudi:
$31.05
Aprire:
$30.42
Volume 24 ore:
569.29K
Relative Volume:
0.61
Capitalizzazione di mercato:
$2.34B
Reddito:
$688.00K
Utile/perdita netta:
$-170.19M
Rapporto P/E:
-9.8836
EPS:
-3.0495
Flusso di cassa netto:
$-154.68M
1 W Prestazione:
-8.00%
1M Prestazione:
-12.97%
6M Prestazione:
+93.08%
1 anno Prestazione:
+25.48%
Intervallo 1D:
$29.60
$30.70
Intervallo di 1 settimana:
$28.00
$33.31
Portata 52W:
$10.91
$35.31
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
30.14 | 2.41B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Why Spyre Therapeutics Inc. stock is popular among millennials2025 Geopolitical Influence & Technical Entry and Exit Tips - ulpravda.ru
Why Spyre Therapeutics Inc. stock remains resilient2025 Market Overview & Verified Entry Point Detection - ulpravda.ru
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Is Spyre Therapeutics Inc. stock a contrarian buy2025 Pullback Review & Entry and Exit Point Strategies - ulpravda.ru
Is Spyre Therapeutics Inc. stock positioned for digital transformationPortfolio Profit Report & Capital Efficient Trading Techniques - ulpravda.ru
Aeglea BioTherapeutics Announces Grants of Inducement Awards - Quantisnow
Turtle Cameron, CEO of Spyre Therapeutics, sells $460k in shares - Investing.com Canada
Institution Moves: Is Spyre Therapeutics Inc stock a contrarian buy2025 Market Sentiment & Verified Entry Point Signals - moha.gov.vn
Spyre Therapeutics stock drops as biotech slides — what SYRE investors watch next - TechStock²
Spyre Therapeutics stock slid 6.6% into the weekend — here’s what matters before Monday’s open - TechStock²
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5% – Time to Sell? - Defense World
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus - TechStock²
Spyre Therapeutics stock sinks 7% today: what’s pressuring SYRE and what investors watch next - ts2.tech
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.5%Time to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Sees Significant Decline in Stock Value - GuruFocus
Spyre Therapeutics: Validated Targets, Optimized Delivery - Seeking Alpha
CapEx per share of Spyre Therapeutics, Inc – SWB:3920 - TradingView — Track All Markets
Spyre Therapeutics Slides Despite Bullish Long-Term Hopes - TipRanks
Street Watch: Is Spyre Therapeutics Inc stock a contrarian buyQuarterly Market Summary & Daily Entry Point Trade Alerts - moha.gov.vn
Trend Recap: What makes Spyre Therapeutics Inc. stock attractive to growth fundsJuly 2025 Earnings & Detailed Earnings Play Alerts - Улправда
Why Spyre Therapeutics Inc. stock is recommended by analystsJuly 2025 Chart Watch & Safe Entry Momentum Stock Tips - Улправда
Will Spyre Therapeutics Inc. stock deliver shareholder value2025 Stock Rankings & Momentum Based Trading Ideas - Улправда
How geopolitical tensions affect Spyre Therapeutics Inc. stock2025 Biggest Moves & Technical Entry and Exit Tips - Улправда
How Spyre Therapeutics Inc. stock responds to policy changesSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at Mizuho - MarketBeat
Citigroup Initiates Coverage on Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat
Mizuho Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target - marketscreener.com
Mizuho Initiates Coverage on Spyre Therapeutics (SYRE) with 'Out - GuruFocus
Biotech Momentum Carries After-Hours Trading Gains - RTTNews
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $52.33 - Defense World
Citigroup Initiates Coverage of Spyre Therapeutics (SYRE) with Buy Recommendation - Nasdaq
Mizuho initiates Spyre Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
SYRE: Citigroup Initiates Coverage with a 'Buy' Rating and $64 P - GuruFocus
Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target - marketscreener.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
60,372,927 Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series A Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain Series B Preferred Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Spyre Therapeutics stock hits 52-week high at 35.0 USD By Investing.com - Investing.com Australia
Spyre Therapeutics stock hits 52-week high at 35.0 USD - Investing.com
Spyre Therapeutics (SYRE): Assessing Valuation After a Sharp Momentum-Driven Share Price Surge - Yahoo Finance
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week HighShould You Buy? - MarketBeat
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring - inkl
Affinity Asset Advisors LLC Raises Stock Holdings in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):